Risk factors increasing the likelihood of AKI occurrence during anti-PD-1/PD-L1 therapy include simultaneous use of proton pump inhibitors (OR 2.38; 95%CI: 1.57–3.62), combined treatment with anti-CTLA-4 drugs (OR 2.71; 95%CI: 1.62–4.53) and lower baseline eGFR (OR 1.99; 95%CI: 1.43–2.76). Here, CD274 is linked to acute kidney injury.